An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C

K. Patel, Y. Benhamou, E. M. Yoshida, K. D. Kaita, S. Zeuzem, M. Torbenson, E. Pulkstenis, G. M. Subramanian, J. G. McHutchison

Research output: Contribution to journalArticle

Abstract

Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to liver biopsy for assessment of histological endpoints of antiviral therapy in chronic hepatitis C (CHC). This study compared two commercially available serum marker panels (HCV FibroSURE™ and FIBROSpect II®) during interferon-based therapy. Ninety-five interferon-naïve patients with genotype 1 CHC were enrolled in a phase 2b, active-controlled study of albinterferon alfa-2b/ribavirin for 48 weeks. Proprietary and simple biochemical marker panels were independently evaluated in serum before and during the study. Baseline liver biopsies were evaluated for METAVIR fibrosis by a single pathologist. Index scores were obtained for HCV FibroSURE (n = 84) and FIBROSpect II (n = 95); mean biopsy length: 17.8 ± 8.0 mm. For detecting fibrosis stages 2-4 (prevalence 23% [22/95] and 21% [18/84]), HCV FibroSURE and FIBROSpect II indicated high sensitivity (1.00 and 0.95, respectively), lower but comparable specificity (0.61 and 0.66, respectively), and a good area under the receiver operating characteristic curve (0.89 and 0.90, respectively). Simple indices had high indeterminate rates (31-40%) at baseline. Patients with a sustained virological response had lower baseline scores than nonresponders, and reduced median percent changes in index scores for HCV FibroSURE (-20.0%vs 2.9%; P = 0.14) and FIBROS Spect II (-6.8%vs 18.4%; P = 0.05). The panels demonstrated comparable performance characteristics for differentiating mild from moderate-severe stage disease in CHC. Lower index scores at baseline that continue to decline likely reflect reduced fibrogenesis activity in patients with successful antiviral responses to therapy.

Original languageEnglish (US)
Pages (from-to)178-186
Number of pages9
JournalJournal of Viral Hepatitis
Volume16
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Chronic Hepatitis C
Fibrosis
Biopsy
Interferons
Antiviral Agents
Biomarkers
Ribavirin
Liver
ROC Curve
Therapeutics
Genotype
Serum
albinterferon alfa-2b

Keywords

  • Albinterferon alfa-2b
  • Chronic hepatitis C
  • Fibrosis
  • FIBROSpect II
  • HCV FibroSURE

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. / Patel, K.; Benhamou, Y.; Yoshida, E. M.; Kaita, K. D.; Zeuzem, S.; Torbenson, M.; Pulkstenis, E.; Subramanian, G. M.; McHutchison, J. G.

In: Journal of Viral Hepatitis, Vol. 16, No. 3, 03.2009, p. 178-186.

Research output: Contribution to journalArticle

Patel, K. ; Benhamou, Y. ; Yoshida, E. M. ; Kaita, K. D. ; Zeuzem, S. ; Torbenson, M. ; Pulkstenis, E. ; Subramanian, G. M. ; McHutchison, J. G. / An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. In: Journal of Viral Hepatitis. 2009 ; Vol. 16, No. 3. pp. 178-186.
@article{c7656f2071a74ca9887e0122bb45c84e,
title = "An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C",
abstract = "Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to liver biopsy for assessment of histological endpoints of antiviral therapy in chronic hepatitis C (CHC). This study compared two commercially available serum marker panels (HCV FibroSURE™ and FIBROSpect II{\circledR}) during interferon-based therapy. Ninety-five interferon-na{\"i}ve patients with genotype 1 CHC were enrolled in a phase 2b, active-controlled study of albinterferon alfa-2b/ribavirin for 48 weeks. Proprietary and simple biochemical marker panels were independently evaluated in serum before and during the study. Baseline liver biopsies were evaluated for METAVIR fibrosis by a single pathologist. Index scores were obtained for HCV FibroSURE (n = 84) and FIBROSpect II (n = 95); mean biopsy length: 17.8 ± 8.0 mm. For detecting fibrosis stages 2-4 (prevalence 23{\%} [22/95] and 21{\%} [18/84]), HCV FibroSURE and FIBROSpect II indicated high sensitivity (1.00 and 0.95, respectively), lower but comparable specificity (0.61 and 0.66, respectively), and a good area under the receiver operating characteristic curve (0.89 and 0.90, respectively). Simple indices had high indeterminate rates (31-40{\%}) at baseline. Patients with a sustained virological response had lower baseline scores than nonresponders, and reduced median percent changes in index scores for HCV FibroSURE (-20.0{\%}vs 2.9{\%}; P = 0.14) and FIBROS Spect II (-6.8{\%}vs 18.4{\%}; P = 0.05). The panels demonstrated comparable performance characteristics for differentiating mild from moderate-severe stage disease in CHC. Lower index scores at baseline that continue to decline likely reflect reduced fibrogenesis activity in patients with successful antiviral responses to therapy.",
keywords = "Albinterferon alfa-2b, Chronic hepatitis C, Fibrosis, FIBROSpect II, HCV FibroSURE",
author = "K. Patel and Y. Benhamou and Yoshida, {E. M.} and Kaita, {K. D.} and S. Zeuzem and M. Torbenson and E. Pulkstenis and Subramanian, {G. M.} and McHutchison, {J. G.}",
year = "2009",
month = "3",
doi = "10.1111/j.1365-2893.2008.01062.x",
language = "English (US)",
volume = "16",
pages = "178--186",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C

AU - Patel, K.

AU - Benhamou, Y.

AU - Yoshida, E. M.

AU - Kaita, K. D.

AU - Zeuzem, S.

AU - Torbenson, M.

AU - Pulkstenis, E.

AU - Subramanian, G. M.

AU - McHutchison, J. G.

PY - 2009/3

Y1 - 2009/3

N2 - Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to liver biopsy for assessment of histological endpoints of antiviral therapy in chronic hepatitis C (CHC). This study compared two commercially available serum marker panels (HCV FibroSURE™ and FIBROSpect II®) during interferon-based therapy. Ninety-five interferon-naïve patients with genotype 1 CHC were enrolled in a phase 2b, active-controlled study of albinterferon alfa-2b/ribavirin for 48 weeks. Proprietary and simple biochemical marker panels were independently evaluated in serum before and during the study. Baseline liver biopsies were evaluated for METAVIR fibrosis by a single pathologist. Index scores were obtained for HCV FibroSURE (n = 84) and FIBROSpect II (n = 95); mean biopsy length: 17.8 ± 8.0 mm. For detecting fibrosis stages 2-4 (prevalence 23% [22/95] and 21% [18/84]), HCV FibroSURE and FIBROSpect II indicated high sensitivity (1.00 and 0.95, respectively), lower but comparable specificity (0.61 and 0.66, respectively), and a good area under the receiver operating characteristic curve (0.89 and 0.90, respectively). Simple indices had high indeterminate rates (31-40%) at baseline. Patients with a sustained virological response had lower baseline scores than nonresponders, and reduced median percent changes in index scores for HCV FibroSURE (-20.0%vs 2.9%; P = 0.14) and FIBROS Spect II (-6.8%vs 18.4%; P = 0.05). The panels demonstrated comparable performance characteristics for differentiating mild from moderate-severe stage disease in CHC. Lower index scores at baseline that continue to decline likely reflect reduced fibrogenesis activity in patients with successful antiviral responses to therapy.

AB - Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to liver biopsy for assessment of histological endpoints of antiviral therapy in chronic hepatitis C (CHC). This study compared two commercially available serum marker panels (HCV FibroSURE™ and FIBROSpect II®) during interferon-based therapy. Ninety-five interferon-naïve patients with genotype 1 CHC were enrolled in a phase 2b, active-controlled study of albinterferon alfa-2b/ribavirin for 48 weeks. Proprietary and simple biochemical marker panels were independently evaluated in serum before and during the study. Baseline liver biopsies were evaluated for METAVIR fibrosis by a single pathologist. Index scores were obtained for HCV FibroSURE (n = 84) and FIBROSpect II (n = 95); mean biopsy length: 17.8 ± 8.0 mm. For detecting fibrosis stages 2-4 (prevalence 23% [22/95] and 21% [18/84]), HCV FibroSURE and FIBROSpect II indicated high sensitivity (1.00 and 0.95, respectively), lower but comparable specificity (0.61 and 0.66, respectively), and a good area under the receiver operating characteristic curve (0.89 and 0.90, respectively). Simple indices had high indeterminate rates (31-40%) at baseline. Patients with a sustained virological response had lower baseline scores than nonresponders, and reduced median percent changes in index scores for HCV FibroSURE (-20.0%vs 2.9%; P = 0.14) and FIBROS Spect II (-6.8%vs 18.4%; P = 0.05). The panels demonstrated comparable performance characteristics for differentiating mild from moderate-severe stage disease in CHC. Lower index scores at baseline that continue to decline likely reflect reduced fibrogenesis activity in patients with successful antiviral responses to therapy.

KW - Albinterferon alfa-2b

KW - Chronic hepatitis C

KW - Fibrosis

KW - FIBROSpect II

KW - HCV FibroSURE

UR - http://www.scopus.com/inward/record.url?scp=60349092622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60349092622&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2893.2008.01062.x

DO - 10.1111/j.1365-2893.2008.01062.x

M3 - Article

C2 - 19175870

AN - SCOPUS:60349092622

VL - 16

SP - 178

EP - 186

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 3

ER -